Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension

Карпов, А. А.; Vaulina, D. D.; Smirnov, Sergey; Moiseeva, O. M.; Галагудза, М. М.

doi:10.1016/j.heliyon.2022.e09014

Cited by 7 publications

(3 citation statements)

References 130 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rats were infused with 20 autologous clots 1 × 1 × 2 mm in size slowly over 5 min. A right ventricular pressure increase exceeding 10 mmHg above baseline pressure after clots infusion was considered as acute PE 18,19 . For few rats, supplementary clots were infused to take the right ventricular pressure exceeding that level.…”

Section: Methodsmentioning

confidence: 99%

“…A right ventricular pressure increase exceeding 10 mmHg above baseline pressure after clots infusion was considered as acute PE. 18 , 19 For few rats, supplementary clots were infused to take the right ventricular pressure exceeding that level. Not eligible for further experiment if the increase of right ventricular pressure did not reach 10 mmHg after the supplemental clot injection.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary embolism induces pneumonia‐like lung injury beyond pulmonary infarction

Wang,

Liu,

Zhou

et al. 2023

Pulm. circ.

View full text Add to dashboard Cite

Patients with pulmonary embolism (PE) commonly manifest concomitant “pneumonia,” which is generally believed to be either a cause (infection) or a consequence (infarction) of PE. This study aimed to clarify the relationship between PE and “pneumonia‐like” lesions beyond pulmonary infection and infarction. Chest computed tomography (CT) images of patients with PE and deep vein thrombosis (DVT) were retrospectively analyzed to compare the incidence of pneumonia lesions. The pathological damage and wet/dry ratio of lung tissues were observed in PE rats and PE plasma‐injected rats. In total, 793 and 914 inpatients were enrolled in the PE and DVT groups, respectively. Pneumonia lesions were observed in 36.9% and 26.3% of patients in the PE and DVT groups, respectively (p < 0.0001). Among PE rats, 33.3% exhibited focal severe lung injury, which closely resembled the pathological damage of community‐acquired pneumonia. The wet/dry ratio was significantly higher in the PE group than in the PE‐control group (4.98 ± 0.08 vs. 4.39 ± 0.06, p < 0.0001). Among PE plasma‐injected rats, individuals with focal proven lung injury were found at all experimental points, with an incidence of 27.6%. The lung wet/dry ratio was significantly higher in the PE plasma group than in the PE‐control plasma group at 1 and 2 h postinjection (5.02 ± 0.12 vs. 4.61 ± 0.06 and 4.76 ± 0.16 vs. 4.34 ± 0.09, respectively; p < 0.05). In conclusion, the manifestation of pneumonia lesions in chest CT images was higher among PE patients than among DVT patients. Plasma of PE rats could induce focal pneumonia‐like lung injury in healthy rats.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Pulmonary embolism induces pneumonia‐like lung injury beyond pulmonary infarction

Wang,

Liu,

Zhou

et al. 2023

Pulm. circ.

View full text Add to dashboard Cite

show abstract

“…Pulmonary embolism (PE) ranks third in prevalence among all cardiovascular diseases [ 1 , 2 ]. It is worth considering that the risk of venous thromboembolism in patients under 45 years varies in the range of 1.0–1.5 per 1000 people per year and almost doubles every decade.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension

Карпов

Mihailova

Shilenko

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism with poor clinical outcomes. Therapeutic approaches to prevention of fibrotic remodeling of the pulmonary vascular bed in CTEPH are limited. In this work, we tested the hypothesis that Janus kinase 1/2 (JAK1/2) inhibition with ruxolitinib might prevent and attenuate CTEPH in a rat model. CTEPH was induced by repeated embolization of the pulmonary artery with partially biodegradable 180 ± 30 μm alginate microspheres. Two weeks after the last injection of microspheres, ruxolitinib was administered orally at doses of 0.86, 2.58, and 4.28 mg/kg per day for 4 weeks. Prednisolone (1.475 mg/kg, i.m.) was used as a reference drug. Ruxolitinib in all doses as well as prednisolone reduced pulmonary vascular wall hypertrophy. Ruxolitinib at a dose of 2.58 mg/kg and prednisolone reduced vascular wall fibrosis. Prednisolone treatment resulted in decreased right ventricular systolic pressure. Pulmonary vascular resistance was lower in the prednisolone and ruxolitinib (4.28 mg/kg) groups in comparison with the placebo group. The plasma level of brain natriuretic peptide was lower in groups receiving ruxolitinib at doses of 2.58 and 4.28 mg/kg versus placebo. This study demonstrated that JAK1/2 inhibitor ruxolitinib dose-dependently reduced pulmonary vascular remodeling, thereby preventing CTEPH formation in rats.

show abstract

The Use of Microencapsulated Autologous Thrombi for Modelling Chronic Thromboembolic Pulmonary Hypertension in Rats

Karpov,

Mihailova,

Cherepanov

et al. 2023

Bull Exp Biol Med

View full text Add to dashboard Cite

Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension

Cited by 7 publications

References 130 publications

Pulmonary embolism induces pneumonia‐like lung injury beyond pulmonary infarction

Pulmonary embolism induces pneumonia‐like lung injury beyond pulmonary infarction

Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension

The Use of Microencapsulated Autologous Thrombi for Modelling Chronic Thromboembolic Pulmonary Hypertension in Rats

Contact Info

Product

Resources

About